

Attorney Docket No.: **PB60024USw**


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Irving, et al.	Date:	September 18, 2009
Serial No.:	10/550,363	Group Art Unit No.:	1649
Filed:	April 15, 2007	Examiner:	Kolker, Daniel E.
For:	Therapeutical Use of Anti-Myelin Associated Glycoprotein (Mag) Antibodies		

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825

- (X) I hereby state that the contents of the paper and computer readable copies of the Sequence Listing (.txt), submitted in accordance with **37 CFR §1.821(c)** and **(e)**, respectively, are the same.
- (X) I hereby state that the submission filed in accordance with **37 CFR §1.821 (g)** does not include new matter.
- (X) I hereby state that the submission filed in accordance with **37 CFR §1.821 (h)** does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with **37 CFR §1.825 (a)**, included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages _____. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(b)**, is the same as the amended Sequence Listing.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(d)**, is identical to that originally filed.

Respectfully submitted,



Jason C. Fedon
Attorney for Applicants
Registration No. 48,138

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-6150
Facsimile (610) 270-5090